Mylan Tries To Escape Pharmacy's EpiPen Antitrust Suit

By Meghan Kelly · December 15, 2020, 5:46 PM EST

Mylan Pharmaceuticals has urged a Kansas federal judge to drop it from a suit alleging it inflated the price for the emergency allergy medication EpiPen, arguing the retail and online pharmacy...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

2:17-md-02785

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Case Title

KPH Healthcare Services, Inc. v. Mylan N.V. et al

Case Number

2:20-cv-02065

Court

Kansas

Nature of Suit

Anti-Trust

Date Filed

February 14, 2020

Featured Stories

The Future of The 340B Rebate Pilot No Photo Available

Yeji Jesse Lee

A federal judge halted a new 340B pilot program, handing a win for safety net healthcare providers. Healthcare attorneys say it's too ... (more story)

Drug Pricing Battles To Watch In 2026 No Photo Available

Mark Payne

With drugmakers already pushing back on drug affordability programs and policies, Law360 looks at the year ahead for litigation focuse... (more story)

SnapChat, Pork And Big Prosecutions: Trials To Watch In 2026 No Photo Available

Cara Salvatore

The coming year is set to bring high-profile trials, including in the criminal case against SCOTUSblog co-founder Tom Goldstein, as we... (more story)